WASHINGTON — The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers.
Briefly, those deals require companies to launch new drugs in the U.S. at net prices roughly equal to those in other wealthy nations, though the precise terms are secret. Three prescription medicines that are set to launch in the coming months will provide the most public view yet of the practical impacts of Trump’s dealmaking.
The drugs are Baxfendy for hypertension from AstraZeneca, the insulin Awiqli from Novo Nordisk, and Veppanu, a cancer drug developed by Arvinas and Pfizer that’s set to be licensed to Rigel Pharmaceuticals. Baxfendy and Veppanu aren’t yet available in other wealthy countries that are used as comparisons for reference pricing.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
